UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration

UCBUCB and Baylor College of Medicine announced that they have started a strategic research alliance, led at Baylor by Professor Huda Zoghbi, that aims to discover new therapeutics to treat neurodegenerative disease.

This research alliance reflects UCB’s strategy to accelerate discovery and development of transformational therapeutics by forging strong partnerships with leading academic partners. Huda Zoghbi is professor in the Departments of Pediatrics, Molecular and Human Genetics, Neurology and Neuroscience at Baylor College of Medicine, investigator at the Howard Hughes Medical Institute and the director of the Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children's Hospital.

The research programme is aligned with a key strategy of UCB NewMedicines to focus on the discovery of medicines targeting pathways with a high level of genetic and human validation. Professor Zoghbi and her collaborators have world leading capabilities in using functional genetics in model organisms to identify therapeutic points of intervention for new medicines.

Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB said: "We cannot accelerate discovery of transformational medicines and create value for patients if we work alone. That is why we have been creating super networks with high quality scientific partners, combining insights from patients with deep understanding of disease mechanisms. This strategic research alliance brings together Huda Zoghbi's world class research with our high quality R&D teams to discover medicines based on genetically validated targets that could transform the lives of people living with severe neurodegenerative disease."

"My team and I are very excited to start this collaboration with UCB as their expertise will complement ours and will ensure that therapeutic targets are swiftly used to discover new medicines for patients suffering from devastating neurodegenerative diseases," Prof. Zoghbi said.

Dr. Paul Klotman, president and CEO of Baylor College of Medicine, said, "These types of collaborations will ensure accelerated results. Dr. Zoghbi is world renowned in neurodegenerative disease research and I’m confident this alliance will lead to improved clinical outcomes."

About UCB UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB).

About Baylor College of Medicine
Baylor College of Medicine in Houston is recognized as a premier academic health sciences center and is known for excellence in education, research and patient care. It is the only private medical school in the greater southwest and is ranked 21st among medical schools for research and 11th for primary care by U.S. News & World Report. Baylor is listed 20th among all U.S. medical schools for National Institutes of Health funding and number one in Texas. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates CHI St. Luke's Health, Baylor St. Luke's Medical Center. Currently, Baylor trains more than 3,000 medical, graduate, nurse anesthesia, physician assistant and orthotics students, as well as residents and post-doctoral fellows.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]